These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 14505894)

  • 21. Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).
    Díez-Domingo J; Ridao-López M; Gutiérrez-Gimeno MV; Puig-Barberá J; Lluch-Rodrigo JA; Pastor-Villalba E
    Vaccine; 2011 Dec; 29(52):9640-8. PubMed ID: 22027484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The heptavalent conjugate pneumococcal vaccine and its implications for managed care--clinical overview and roundtable discussions.
    Alexander PG; Chartrand SA; Davies TJ; Gaines BM; Oster G; Shurin P; Tamsky L; Thornton DK; Wittert W
    Manag Care Interface; 2001; Suppl C():10-28; quiz 29-30. PubMed ID: 11724029
    [No Abstract]   [Full Text] [Related]  

  • 23. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making.
    Welte R; van den Dobbelsteen G; Bos JM; de Melker H; van Alphen L; Spanjaard L; Rümke HC; Postma MJ
    Vaccine; 2004 Dec; 23(4):470-9. PubMed ID: 15530695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States.
    Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE;
    Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
    Zhang XH; Leeuwenkamp O; Oh KB; Lee YE; Kim CM
    Hum Vaccin Immunother; 2018 Jan; 14(1):85-94. PubMed ID: 29115905
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiological impact and cost-effectiveness of introducing vaccination against serogroup B meningococcal disease in France.
    Lecocq H; Parent du Châtelet I; Taha MK; Lévy-Bruhl D; Dervaux B
    Vaccine; 2016 Apr; 34(19):2240-50. PubMed ID: 27002504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
    Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
    BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vaccine-preventable severe morbidity and mortality caused by meningococcus and pneumococcus: A population-based study in France.
    Lorton F; Chalumeau M; Assathiany R; Martinot A; Bucchia M; Roué JM; Bourgoin P; Chantreuil J; Boussicault G; Gaillot T; Saulnier JP; Caillon J; Levy C; Cohen R; Gras-Le Guen C; Launay E
    Paediatr Perinat Epidemiol; 2018 Sep; 32(5):442-447. PubMed ID: 30170336
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of the CRM-based 7-valent pneumococcal conjugated vaccine (PCV7) in Argentina.
    Giglio ND; Cane AD; Micone P; Gentile A
    Vaccine; 2010 Mar; 28(11):2302-10. PubMed ID: 20064478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Advisory Committee on Immunization Practices
    MMWR Recomm Rep; 2000 Oct; 49(RR-9):1-35. PubMed ID: 11055835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy.
    Castiglia P; Pradelli L; Castagna S; Freguglia V; Palù G; Esposito S
    Hum Vaccin Immunother; 2017 Oct; 13(10):2307-2315. PubMed ID: 28700264
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
    Marchetti M; Colombo GL
    Vaccine; 2005 Aug; 23(37):4565-76. PubMed ID: 15992969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China.
    Caldwell R; Roberts CS; An Z; Chen CI; Wang B
    BMC Infect Dis; 2015 Jul; 15():284. PubMed ID: 26206275
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysis.
    Gasparini R; Landa P; Amicizia D; Icardi G; Ricciardi W; de Waure C; Tanfani E; Bonanni P; Lucioni C; Testi A; Panatto D
    Hum Vaccin Immunother; 2016 Aug; 12(8):2148-2161. PubMed ID: 27163398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of heptavalent conjugate pneumococcal vaccine (Prevenar) in Germany: considering a high-risk population and herd immunity effects.
    Lloyd A; Patel N; Scott DA; Runge C; Claes C; Rose M
    Eur J Health Econ; 2008 Feb; 9(1):7-15. PubMed ID: 17333089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.
    Christensen H; Trotter CL; Hickman M; Edmunds WJ
    BMJ; 2014 Oct; 349():g5725. PubMed ID: 25301037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine.
    McIntosh ED; Conway P; Willingham J; Lloyd A
    Vaccine; 2003 Jun; 21(19-20):2564-72. PubMed ID: 12744892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of pneumococcal vaccination for infants in China.
    Maurer KA; Chen HF; Wagner AL; Hegde ST; Patel T; Boulton ML; Hutton DW
    Vaccine; 2016 Dec; 34(50):6343-6349. PubMed ID: 27810315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cost effectiveness of vaccination against pneumococcal bacteremia in the elderly: the results in Belgium].
    De Graeve D; Verhaegen J; Ament A; Baltussen R
    Acta Clin Belg; 2000; 55(5):257-65. PubMed ID: 11109640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.